Brii Biosciences Limited

Brii Biosciences Limited (Brii Bio) is a biotechnology company focusing on the research and development of therapies for the treatment of infectious and central nervous system diseases. Brii Bio is developing therapies, including BRII-179, BRII-835, and BRII-877 for Hepatitis B; BRII-732 and BRII-753 for HIV. The company also develops BRII-296 for PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. Brii Bio was incorporated in 2017 and is headquartered in Beijing, China. Brii Bio aims to develop first-in-class and/or different-in-class treatment options for infectious diseases with high unmet medical needs. The company is well-funded, and the company has cash reserves of US$335.7 million to propel operations. Brii Bio is progressing multiple ongoing combination studies with differentiated HBV candidates, including elebsiran, an HBV-targeting siRNA; BRII-179, a recombinant protein-based HBV immunotherapeutic. The company has a partnership with Vir Biotechnology for tobevibart.